iBio (IBIO) 10-Q 9 Nov 17 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Sep. 30, 2017	Nov. 09, 2017
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Entity Registrant Name	iBio, Inc.
Entity Central Index Key	1,420,720
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	IBIO
Entity Common Stock, Shares Outstanding		92,818,510

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Current assets:
Cash	$ 5,916	$ 8,088
Accounts receivable - trade	260	175
Work in process	0	26
Prepaid expenses and other current assets	206	283
Total Current Assets	6,382	8,572
Fixed assets, net of accumulated depreciation	25,268	25,589
Intangible assets, net of accumulated amortization	1,757	1,823
Security deposit	26	26
Total Assets	33,433	36,010
Current liabilities:
Accounts payable (related party of $56 and $87 as of September 30, 2017 and June 30, 2017, respectively)	596	749
Accrued expenses (related party of $778 and $650 as of September 30, 2017 and June 30, 2017, respectively)	1,047	924
Capital lease obligation - current portion	187	183
Deferred revenue	276	157
Total Current Liabilities	2,106	2,013
Capital lease obligation - net of current portion	25,034	25,082
Total Liabilities	27,140	27,095
Commitments and Contingencies
iBio, Inc. Stockholders’ Equity:
Preferred stock - $0.001 par value; 1,000,000 shares authorized; 1 share issued and outstanding as of both September 30, 2017 and June 30, 2017	0	0
Common stock - $0.001 par value; 175,000,000 shares authorized; 92,818,510 and 89,118,510 shares issued and outstanding as of September 30, 2017 and June 30, 2017, respectively	93	89
Additional paid-in capital	82,178	80,977
Accumulated other comprehensive loss	(29)	(29)
Accumulated deficit	(75,949)	(72,123)
Total iBio, Inc. Stockholders’ Equity	6,293	8,914
Noncontrolling interest	0	1
Total Equity	6,293	8,915
Total Liabilities and Equity	$ 33,433	$ 36,010

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Accounts payable, related parties	$ 56	$ 87
Accrued expenses, related parties	$ 778	$ 650
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	1	1
Preferred stock, shares outstanding (in shares)	1	1
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	175,000,000	175,000,000
Common stock, shares issued (in shares)	92,818,510	89,118,510
Common stock, shares outstanding (in shares)	92,818,510	89,118,510

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Revenues	$ 122	$ 135
Operating expenses:
Research and development (related parties of $176 and $239), net of $44 and $36 in grant income	985	820
General and administrative (related parties of $206 and $175)	2,498	2,469
Total operating expenses	3,483	3,289
Operating loss	(3,361)	(3,154)
Other income (expense):
Interest expense (related party of $480 and $483)	(480)	(483)
Interest income	5	13
Royalty income	9	12
Total other income (expense)	(466)	(458)
Consolidated net loss	(3,827)	(3,612)
Net loss attributable to noncontrolling interest	1	551
Net loss attributable to iBio, Inc.	(3,826)	(3,061)
Preferred stock dividends	(66)	0
Net loss available to iBio, Inc.	(3,892)	(3,061)
Comprehensive loss:
Consolidated net loss	(3,827)	(3,612)
Other comprehensive loss - foreign currency translation adjustments	0	0
Comprehensive loss	$ (3,827)	$ (3,612)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted	$ (0.04)	$ (0.03)
Weighted-average common shares outstanding - basic and diluted	91,853	89,109

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Operating expenses research and development, related party	$ 176	$ 239
Operating expenses general and administrative, related party	206	175
Interest Expense, Related Party	480	483
Revenue from Grants	$ 44	$ 36

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Equity - 3 months ended Sep. 30, 2017 - USD ($) shares in Thousands, $ in Thousands	Total	Accumulated Other Comprehensive Loss [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Jun. 30, 2017	$ 8,915	$ (29)	$ 0	$ 89	$ 80,977	$ (72,123)	$ 1
Balance (in shares) at Jun. 30, 2017			0	89,119
Sale of common stock	1,000	0	$ 0	$ 3	997	0	0
Sale of common stock (in shares)			0	2,500
Commitment fee for issuance of common stock	0	0	$ 0	$ 1	(1)	0	0
Commitment fee for issuance of common stock (in shares)			0	1,200
Share-based compensation	205	0	$ 0	$ 0	205	0	0
Foreign currency translation adjustment	0	0	0	0	0	0	0
Net loss	(3,827)	0	0	0	0	(3,826)	(1)
Balance at Sep. 30, 2017	$ 6,293	$ (29)	$ 0	$ 93	$ 82,178	$ (75,949)	$ 0
Balance (in shares) at Sep. 30, 2017			0	92,819

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities:
Consolidated net loss	$ (3,827)	$ (3,612)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Share-based compensation	205	265
Amortization of intangible assets	85	88
Depreciation	338	324
Changes in operating assets and liabilities:
Accounts receivable - trade	(85)	315
Accounts receivable - unbilled	0	61
Work in process	26	22
Prepaid expenses and other current assets	77	131
Security deposit	0	2
Accounts payable	(78)	53
Accrued expenses	123	102
Deferred revenue	119	(24)
Net cash used in operating activities	(3,017)	(2,273)
Cash flows from investing activities:
Additions to intangible assets	(15)	(202)
Purchases of fixed assets	(96)	(400)
Net cash used in investing activities	(111)	(602)
Cash flows from financing activities:
Proceeds from sale of common stock	1,000	0
Payment of capital lease obligation	(44)	(41)
Net cash provided by (used in) financing activities	956	(41)
Net decrease in cash	(2,172)	(2,916)
Cash - beginning of period	8,088	23,014
Cash - end of period	5,916	20,098
Schedule of non-cash activities:
Unpaid intangible assets included in accounts payable	7	184
Intangible assets included in accounts payable in FY 2017, paid in FY 2018	11	0
Unpaid fixed assets included in accounts payable	9	71
Fixed assets included in accounts payable in FY 2017, paid in FY 2018	87	0
Supplemental cash flow information:
Cash paid during the period for interest	$ 481	$ 484

Nature of Business

Nature of Business	3 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Nature of Business iBio, Inc. and Subsidiaries (“iBio” or the “Company”) is a biotechnology company focused on using our proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators and third-party customers as well as developing and commercializing our own product candidates. iBio was established as a public company in August 2008 as the result of a spinoff from Integrated BioPharma, Inc. The Company operates in one business segment under the direction of its Executive Chairman. The Company’s wholly-owned and majority-owned subsidiaries are as follows: iBIO DO BRASIL BIOFARMACÊUTICA LTDA iBio Manufacturing LLC iBio CDMO LLC 100 15 30 70 On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate, pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate in exchange for one share of the Company’s iBio CMO Preferred Tracking Stock, par value $ 0.001 99.99 iBio CDMO’s operations take place in Bryan, Texas in a facility controlled by another affiliate of Eastern (the “Second Eastern Affiliate”) as sublandlord. The facility is a 139,000 34

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2. Basis of Presentation Interim Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission. Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2017, from which the accompanying condensed consolidated balance sheet dated June 30, 2017 was derived. Principles of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Foreign Currency The Company accounts for foreign currency translation pursuant to Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 830, “ Foreign Currency Matters Going Concern Since its spin-off from Integrated BioPharma, Inc. in August 2008, the Company has incurred significant losses and negative cash flows from operations. As of September 30, 2017 75.9 3.8 3.0 The Company has historically financed its activities through the sale of common stock and warrants. Through September 30, 2017, the Company has dedicated most of its financial resources to research and development, including the development and validation of its own technologies and the development of a proprietary therapeutic product against fibrosis based upon those technologies, advancing its intellectual property, the build-out and recommissioning of its CDMO facility, and general and administrative activities. As of September 30, 2017, the Company has not completed development of or commercialized any vaccine or therapeutic product candidates. As such, the Company expects to continue to incur significant expenses and operating losses for at least the next year. The Company anticipates that its expenses and losses will increase substantially if the Company: ⋅ initiates clinical trials of its product candidates; ⋅ continues the research and development of our product candidates; ⋅ seeks to discover additional product candidates; and ⋅ adds operational, financial and management information systems and personnel, including personnel to support our product development and manufacturing efforts. To become and remain profitable, the Company must succeed in commercializing its technologies or the Company, alone or with its licensees, must succeed in developing and eventually commercializing products that generate significant revenue. In addition, profitability will depend on continuing to attract and maintain customers for the development, manufacturing and technology transfer services offered by the Company’s subsidiary iBio CDMO. On July 24, 2017, the Company entered into a common stock purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”), an Illinois limited liability company, pursuant to which Lincoln Park has agreed to purchase from the Company up to an aggregate of $16,000,000 of the Company’s common stock (subject to certain limitations) from time to time over the 36-month term of the agreement (the “Lincoln Park Purchase Agreement”). As a result, on July 24, 2017, 1,200,000 shares of the Company’s common stock were issued to Lincoln Park as consideration for Lincoln Park’s commitment to purchase shares of its common stock under the agreement, and the Company sold 2,500,000 1,000,000 The extent to which the Company utilizes the purchase agreement with Lincoln Park as a source of funding will depend on a number of factors, including the prevailing market price of the Company’s common stock, the volume of trading in the Company’s common stock and the extent to which the Company is able to secure funds from other sources. The number of shares that the Company may sell to Lincoln Park under the purchase agreement on any given day and during the term of the agreement is limited. Additionally, the Company and Lincoln Park may not effect any sales of shares of our common stock under the purchase agreement during the continuance of an event of default under the purchase agreement. The history of significant losses, the negative cash flow from operations, the limited cash resources currently on hand and the dependence by the Company on its ability – about which there can be no certainty – to obtain additional financing to fund its operations after the current cash resources are exhausted raises substantial doubt about the Company’s ability to continue as a going concern. These financial statements were prepared under the assumption that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. The Company plans to fund its future business operations using cash on hand, through proceeds from the sale of additional equity or other securities, including sales of common stock to Lincoln Park pursuant to the common stock purchase agreement entered into on July 24, 2017, and through proceeds realized in connection with license and collaboration arrangements and the operation of our subsidiary, iBio CDMO. The Company cannot be certain that such funding will be available on favorable terms or available at all. To the extent that the Company raises additional funds by issuing equity securities, its stockholders may experience significant dilution. If the Company is unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and the Company may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of its proprietary technologies; b) seek collaborators for its technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that it would otherwise seek to develop or commercialize; or d) possibly cease operations.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 3 of the Notes to Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2017. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates. The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. Grant income amounted to approximately $ 44,000 36,000 Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. Work in process totaled $ 0 26,000 The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5). The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23 The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period Effective June 30, 2017, the Company adopted ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern On January 1, 2017, the Company adopted ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers. In May 2016, the FASB issued ASU 2016-12, " Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In October 2016, the FASB issued ASU 2016-16, “ Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued ASU 2016-17, “ Consolidation (Topic 810): Interests Held Through Related Parties That Are Under Common Control In January 2017, the FASB issued ASU 2017-01, “ Business Combinations (Topic 805): Clarifying the Definition of a Business In May 2017, the FASB issued ASU 2017-09, “ Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting ” Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

Financial Instruments and Fair

Financial Instruments and Fair Value Measurement	3 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	4. Financial Instruments and Fair Value Measurement The carrying values of cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses in the Company’s condensed consolidated balance sheets approximated their fair values as of September 30, 2017 and June 30, 2017 due to their short-term nature. The carrying value of the capital lease obligation approximated its fair value as of September 30, 2017 and June 30, 2017 as the interest rate used to discount the lease payments approximated market.

Fixed Assets

Fixed Assets	3 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Fixed Assets iBio CDMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Eastern Affiliate under a 34 The economic substance of the sublease is that the Company is financing the acquisition of the facility and equipment and, accordingly, the facility and equipment are recorded as assets and the lease is recorded as a liability. As the sublease involves real estate and equipment, the Company separated the equipment component and accounted for the facility and equipment as if each was leased separately. September 30, June 30, Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 340 332 Medical equipment 914 905 Office equipment and software 256 256 27,510 27,493 Accumulated depreciation – assets under capital lease (2,111) (1,805) Accumulated depreciation – other (131) (99) (2,242) (1,904) Net fixed assets $ 25,268 $ 25,589 Depreciation expense was approximately $ 338,000 324,000 306,000 311,000

Intangible Assets

Intangible Assets	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	6. Intangible Assets The Company has two categories of intangible assets – patents and other intellectual property. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology (“Fraunhofer”), pursuant to a Technology Transfer Agreement, as amended (the “TTA”). The Company designates such technology further developed by and acquired from Fraunhofer as iBioLaunch™ technology or as iBioModulator™ technology. The value on the Company’s books attributed to patents owned or controlled by the Company is based only on payments for services and fees related to the protection of the Company’s patent portfolio. The intellectual property also includes certain trademarks. In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the “Licensed Technology”). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (“IND”) – initially became due on December 1, 2015, and on August 11, 2016, the agreement was amended and subsequent six-month extensions have been automatically granted extending the due date until December 31, 2017. The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 16 23 September 30, June 30, Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,364 2,346 5,464 5,446 Intellectual property – accumulated amortization (2,127) (2,088) Patents – accumulated amortization (1,580) (1,535) (3,707) (3,623) Net intangible assets $ 1,757 $ 1,823 Amortization expense was approximately $ 85,000 88,000

Significant Vendors

Significant Vendors	3 Months Ended
	Sep. 30, 2017
Significant Vendor [Abstract]
Significant Vendor Disclosures [Text Block]	Significant Vendors Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici Biotech, LLC (“Novici”) in which iBio’s President is a minority stockholder. Novici performs laboratory feasibility analyses of gene expression, protein purification and preparation of research samples. In addition, the Company and Novici collaborate on the development of new technologies and product candidates for exclusive worldwide commercial use by the Company. The accounts payable balance includes amounts due to Novici of approximately $ 56,000 87,000 176,000 239,000 Fraunhofer Previously, Fraunhofer was the Company’s most significant vendor solely on the basis of the three-party Yellow Fever vaccine development program among Fiocruz/Bio-Manguinhos, the Company, and Fraunhofer (described in greater detail below). The accounts payable balance under this three-party agreement includes amounts due Fraunhofer of approximately $ 75,000 On January 4, 2011, the Company entered into the Collaboration and License Agreement (the “CLA”) which is a three-party agreement involving the Company, Fraunhofer and Fiocruz, a public entity, member of the Indirect Federal Public Administration and linked to the Health Ministry of Brazil, acting through its unit Bio-Manguinhos. The CLA provides for the development of a Yellow Fever vaccine to be manufactured and distributed within Latin America and Africa by Fiocruz. The CLA was supplemented by a bilateral agreement between iBio and Fraunhofer dated December 27, 2010 in which the Company engaged Fraunhofer as a contractor to provide the research and development services (both, together, the “Agreement”). The services were billed to Fiocruz at Fraunhofer’s cost, so the Company’s revenue was equivalent to expense and there was no profit. On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) which provides for revised research and development, work plans, reporting, objectives, estimated budget, and project billing process. In Fiscal 2018 and Fiscal 2017, under the Amended Agreement, the Company recognized revenue of $ 0 62,000 In September 2013, the Company and Fraunhofer completed the Terms of Settlement for the TTA Seventh Amendment (the “Settlement Agreement”). Under the terms of the Settlement Agreement various contractual obligations existing at June 30, 2013 were released, terminated or modified. See Note 14 - Commitments and Contingencies for significant modifications. On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov, Fraunhofer's Executive Director. On November 3, 2017, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer-Gesellschaft, the European unit of Fraunhofer. This complaint follows iBio’s pending litigation filed in March 2015 against Fraunhofer USA, Inc., the U.S. unit of Fraunhofer. See Note 14 - Lawsuits for additional information.

Capital Lease Obligation

Capital Lease Obligation	3 Months Ended
	Sep. 30, 2017
Leases, Capital [Abstract]
Leases of Lessee Disclosure [Text Block]	Capital Lease Obligation As discussed above, iBio CDMO is leasing its facility in Bryan, Texas as well as certain equipment from the Second Eastern Affiliate under a 34-year sublease (the “Sublease”). iBio CDMO began operations at the facility on December 22, 2015 pursuant to agreements between iBio CDMO and the Second Eastern Affiliate granting iBio CDMO temporary rights to access the facility. These temporary agreements were superseded by the Sublease Agreement, dated January 13, 2016, between iBio CDMO and the Second Eastern Affiliate. The 34 2,100,000 In addition to the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMO’s applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $17,000 and $16,000 for the three months ended September 30, 2017 and 2016, respectively. Interest expense incurred under the capital lease obligation amounted to approximately $ 480,000 484,000 Fiscal period ending on September 30,: Principal Interest Total 2018 $ 186,593 $ 1,913,407 $ 2,100,000 2019 201,198 1,898,802 2,100,000 2020 216,947 1,883,053 2,100,000 2021 233,928 1,866,072 2,100,000 2022 252,238 1,847,762 2,100,000 Thereafter 24,129,294 33,620,706 57,750,000 Total minimum lease payments 25,220,198 $ 43,029,802 $ 68,250,000 Less: current portion (186,593) Long-term portion of minimum lease obligations $ 25,033,605

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Sep. 30, 2017
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Stockholders’ Equity Preferred Stock The Company’s Board of Directors is authorized to issue, at any time, without further stockholder approval, up to 1 iBio CMO Preferred Tracking Stock On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of a newly created iBio CMO Preferred Tracking Stock, par value $ 0.001 29,990,000 13 99.99 0.01 As described below under “ Eastern – Share Purchase Agreements On February 23, 2017, the Board of Directors of the Company created the Preferred Tracking Stock out of the Company’s 1 1. The Preferred Tracking Stock accrues dividends at the rate of 2 156,000 2. The holders of Preferred Tracking Stock, voting separately as a class, are entitled to approve by the affirmative vote of a majority of the shares of Preferred Tracking Stock outstanding any amendment, alteration or repeal of any of the provisions of, or any other change to, the Certificate of Incorporation of the Company or the Certificate of Designation that adversely affects the rights, powers or privileges of the Preferred Tracking Stock, any increase in the number of authorized shares of Preferred Tracking Stock, the issuance or sale of any additional shares of Preferred Tracking Stock or any securities convertible into or exercisable or exchangeable for Preferred Tracking Stock, the creation or issuance of any shares of any additional class or series of capital stock unless the same ranks junior to the Preferred Tracking Stock, or the reclassification or alteration of any existing security of the Company that is junior to or pari passu with the Preferred Tracking Stock, if such reclassification or alteration would render such other security senior to the Preferred Tracking Stock. 3. Except as required by applicable law, the holders of Preferred Tracking Stock have no other voting rights. 4. No dividend may be declared or paid or set aside for payment or other distribution declared or made upon the Company’s common stock and no common stock may be redeemed, purchased or otherwise acquired for any consideration by the Company unless all accrued dividends on all outstanding shares of Preferred Tracking Stock are paid in full. At the election of the Company or holders of a majority outstanding shares of Preferred Tracking Stock, each outstanding share of Preferred Tracking Stock may be exchanged for 29,990,000 units of limited liability company interests of iBio CDMO. Such exchange may be effected only after March 31, 2018, or in connection with a winding up, liquidation or deemed liquidation (such as a merger) of the Company or iBio CDMO. In addition, such exchange will take effect upon a change in control of iBio CDMO. Common Stock As of September 30, 2017 and 2016, the Company was authorized to issue up to 175 15 Recent issuances of common stock include the following: Lincoln Park Purchase Agreement On July 24, 2017, we entered into the Lincoln Park Purchase Agreement pursuant to which Lincoln Park has agreed to purchase from us up to an aggregate of $ 16.0 As a result, on July 24, 2017, 1,200,000 16 2,500,000 0.40 1,000,000 Under the terms and subject to the conditions of the Lincoln Park Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to, an additional $ 15.0 As contemplated by the Lincoln Park Purchase Agreement, and so long as the closing price of the Company’s common stock exceeds $ 0.25 100,000 1.0 In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional purchases if the closing sale price of the common stock exceeds certain threshold prices as set forth in the purchase agreement. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the purchase agreement if it would result in Lincoln Park beneficially owning more than 9.99% of its common stock. There are no trading volume requirements or restrictions under the purchase agreement nor any upper limits on the price per share that Lincoln Park must pay for shares of common stock. The Lincoln Park Purchase Agreement and the registration rights agreement contain customary representations, warranties, agreements and conditions to completing future sale transactions, indemnification rights and obligations of the parties. The Company has the right to terminate the purchase agreement at any time, at no cost or penalty. During any “event of default” under the purchase agreement, all of which are outside of Lincoln Park’s control, Lincoln Park does not have the right to terminate the purchase agreement; however, the Company may not initiate any regular or other purchase of shares by Lincoln Park, until such event of default is cured. In addition, in the event of bankruptcy proceedings by or against the Company, the purchase agreement will automatically terminate. Actual sales of shares of common stock to Lincoln Park under the purchase agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. Lincoln Park has no right to require any sales by the Company, but is obligated to make purchases from the Company as it directs in accordance with the purchase agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company’s shares. Aspire Capital – 2015 Facility On May 15, 2015, the Company entered into a common stock purchase agreement (the “2015 Aspire Purchase Agreement”) with Aspire Capital, pursuant to which the Company has the option to require Aspire Capital to purchase up to an aggregate of $ 15.0 450,000 (the “Commitment Shares”) No shares have been sold under the 2015 Facility as of the date of the filing of this report and the Eastern – Share Purchase Agreements On January 13, 2016, the Company entered into a share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 3,500,000 2,177,000 1,784,000 0.53 945,000 On January 13, 2016, the Company entered into a separate share purchase agreement with Eastern pursuant to which Eastern agreed to purchase 6,500,000 0.622 6,500,000 6,500,000 4,043,000 38 On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of a newly created iBio CMO Preferred Tracking Stock, par value $ 0.001 29,990,000 13 99.99 0.01

Earnings (Loss) Per Common Shar

Earnings (Loss) Per Common Share	3 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	10. Earnings (Loss) Per Common Share Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. Three Months ended 2017 2016 Basic and diluted numerator: Net loss attributable to iBio, Inc. stockholders $ (3,826) $ (3,061) Preferred stock dividends (66) — Net loss available to iBio, Inc. stockholders $ (3,892) $ (3,061) Basic and diluted denominator: Weighted-average common shares outstanding 91,853 89,109 Per share amount $ (0.04) $ (0.03) In Fiscal 2018 and Fiscal 2017, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September 30, 2017 and 2016, shares issuable which could potentially dilute future earnings included approximately 13.6 12.3

Share-Based Compensation

Share-Based Compensation	3 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	Share-Based Compensation Three Months Ended 2017 2016 Research and development $ 14 $ 6 General and administrative 191 259 Total $ 205 $ 265 Stock Options On August 12, 2008, the Company adopted the iBioPharma 2008 Omnibus Equity Incentive Plan (the “Plan”) for employees, officers, directors and external service providers. The original Plan provided that the Company may grant options to purchase stock and/or make awards of restricted stock up to an aggregate amount of 10 1.45 Issuance of stock options during Fiscal 2018 were as follows On July 1, 2017, the Company granted stock options to an employee to purchase 50,000 0.40 Stock Weighted- Weighted- Aggregate Outstanding as of July 1, 2017 13,548,334 $ 1.21 5.8 $ 138 Granted 50,000 0.40 Outstanding as of September 30, 2017 13,598,334 $ 1.21 5.6 $ 83 Vested and, as of September 30, 2017, expected to vest 13,543,932 $ 1.21 5.6 $ 83 Exercisable as of September 30, 2017 10,911,679 $ 1.30 4.8 $ 83 The weighted-average grant date fair value of stock options granted during the three months ended September 30, 2017 was $0.34 per share. As of September 30, 2017, there was approximately $ 922,000 1.6 The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: Risk-free interest rate 2.23 % Dividend yield 0 % Volatility 103.10 % Expected term (in years) 9

Related Party Transactions

Related Party Transactions	3 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transactions Novici Biotech, LLC In January 2012, the Company entered into an agreement with Novici in which iBio’s President is a minority stockholder. See Note 7. Agreements with Eastern Capital Limited and its Affiliates As more fully discussed in Note 9, the Company entered into two share purchase agreements with Eastern and sold 10 0.622 6,220,000 1,784,000 0.53 945,520 Concurrently with the execution of the Purchase Agreements, iBio entered into a contract manufacturing joint venture with an affiliate of Eastern to develop and manufacture plant-made pharmaceuticals through iBio’s recently formed subsidiary, iBio CDMO. The Eastern Affiliate contributed $ 15.0 30 70 In connection with the joint venture, the Second Eastern Affiliate, which controls the subject property as sublandlord, granted iBio CDMO a 34-year sublease of a Class A life sciences building in Bryan, Texas, on the campus of Texas A&M University, designed and equipped for plant-made manufacture of biopharmaceuticals. Accrued expenses at September 30, 2017 and June 30, 2017 due to the Second Eastern Affiliate amounted to $ 778,000 650,000 184,000 167,000 480,000 483,000 A three-year standstill agreement (the “Standstill Agreement”) that took effect upon the issuance of the Eastern Shares pursuant to the 6,500,000 38 On February 23, 2017, the Company entered into an exchange agreement with the Eastern Affiliate pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by the Eastern Affiliate and issued one share of the iBio CMO Preferred Tracking Stock, par value $ 0.001 29,990,000 13 99.99 0.01 Operating Lease with Minority Stockholder The Company is leasing office space on a month-to-month basis from an entity owned by a minority stockholder of the Company. Rent was $ 2,200 2,500 7,500 22,500 7,500

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income Taxes The Company recorded no income tax expense for the three months ended September 30, 2017 and 2016 because the estimated annual effective tax rate was zero. As of September 30, 2017, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies Agreements In September 2013, the Company and Fraunhofer entered into an agreement, the Terms of Settlement for the TTA Seventh Amendment (the “2013 Settlement Agreement”). Under the terms of the 2013 Settlement Agreement, various payment obligations, including accrued payment obligations existing at June 30, 2013, were released, terminated or modified. The significant modifications are of follows: The Company’s obligation under the TTA, prior to the 2013 Settlement Agreement, to make three $ 1 The Company’s obligation to remit to Fraunhofer minimum annual royalty payments in the amount of $ 200,000 4 On June 12, 2014, Fiocruz, Fraunhofer and iBio executed an amendment to the CLA (the “Amended Agreement”) to create a new research and development plan for the development of a recombinant Yellow Fever vaccine providing revised reporting, objectives, estimated budget, and project billing process. By its execution of the Amended Agreement, iBio again engaged Fraunhofer to act as the Company’s subcontractor for performance of research and development services for the new research and development plan covered by the Amended Agreement and to have Fraunhofer bill Fiocruz directly on behalf of the Company at the rates, amounts and times provided in the Amended Agreement with the proceeds of such billings and only the proceeds paid to Fraunhofer for its services so the Company’s expense is equal to its revenue and no profit would be recognized for these activities under the Amended Agreement. For the year ended June 30, 2015, $ 2.1 3.0 On January 14, 2014 (the “Effective Date”), the Company entered into an exclusive worldwide License Agreement (“LA”) with the University of Pittsburgh (“UP”) covering all of the U.S. and foreign patents and patent applications and related intellectual property owned by UP pertinent to the use of endostatin peptides for the treatment of fibrosis. The Company paid an initial license fee of $ 20,000 30,627 25,000 150,000 On December 30, 2013, the Company entered into a Project Agreement with the Medical University of South Carolina (“MUSC”) providing for the performance of research and development services by MUSC related to peptides for the treatment of fibrosis. The agreement requires the Company to make payments totaling $ 78,000 December 31, 2015 161,754 Lawsuits On March 17, 2015, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer and Vidadi Yusibov (“Yusibov”), Fraunhofer’s Executive Director, seeking monetary damages and equitable relief based on Fraunhofer’s material and continuing breaches of their contracts with the Company. On September 16, 2015, the Company voluntarily dismissed its action against Yusibov, without prejudice, and thereafter on September 29, 2015, the Company filed a Verified Amended Complaint against Fraunhofer alleging material breaches of its agreements with the Company and seeking monetary damages and equitable relief against Fraunhofer. The Court bifurcated the action to first resolve the threshold question in the case–the scope of iBio’s ownership of the technology developed or held by Fraunhofer–before proceeding with the rest of the case and the parties stipulated their agreement to that approach. After considering the parties’ written submissions and oral argument, the Court resolved the threshold issue in favor of iBio on July 29, 2016, holding that iBio owns all proprietary rights of any kind to all plant-based technology of Fraunhofer developed or held as of December 31, 2014, including know-how, and was entitled to receive a technology transfer from Fraunhofer. Fraunhofer’s motion to dismiss iBio’s contract claims was denied by the Court on February 24, 2017. The Court at that time also granted, over Fraunhofer’s opposition, iBio’s motion to supplement and amend the Complaint to add additional state law claims against Fraunhofer. Fraunhofer filed an answer and counterclaims in March 2017, but in May 2017, Fraunhofer obtained new counsel, and with iBio’s agreement (as a matter of procedure), filed an amended answer and amended counterclaims in July 2017. The Company replied to those counterclaims on August 9, 2017 and included certain counter-counterclaims, which Fraunhofer moved to dismiss on August 30, 2017. In November 2017, the Company engaged new counsel to further lead its litigation efforts, and on November 3, 2017, the Company filed a Verified Complaint in the Court of Chancery of the State of Delaware against Fraunhofer-Gesellschaft, the European unit of Fraunhofer. This complaint follows iBio’s pending litigation filed in March 2015, described above, against Fraunhofer USA, Inc., the U.S. unit of Fraunhofer. The parties have continued to proceed with written discovery. The Company is unable to predict the further outcome of this action at this time.

Segment Reporting

Segment Reporting	3 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	15. Segment Reporting In accordance with FASB ASC 280, “ Segment Reporting Three Months Ended September 30, 2017 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 84 $ 38 $ - $ 122 Revenues – intersegment 301 210 (511) - Research and development 618 484 (117) 985 General and administrative 1,099 1,698 (299) 2,498 Operating loss (1,332) (2,029) - (3,361) Interest expense - (480) - (480) Interest and other income 12 2 - 14 Consolidated net loss (1,321) (2,506) - (3,827) Total assets 18,810 27,485 (12,862) 33,433 Fixed assets, net 7 25,261 - 25,268 Intangible assets, net 1,757 - - 1,757 Depreciation expense 1 337 - 338 Amortization of intangible assets 85 - - 85 Three Months Ended September 30, 2016 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 86 $ 49 $ - $ 135 Revenues – intersegment 152 182 (334) - Research and development 684 321 (185) 820 General and administrative 1,347 1,271 (149) 2,469 Operating loss (1,793) (1,361) - (3,154) Interest expense - (483) - (483) Interest and other income 18 7 - 25 Consolidated net loss (1,775) (1,837) - (3,612) Total assets 11,810 36,330 (49) 48,091 Fixed assets, net 8 25,572 - 25,580 Intangible assets, net 2,023 - - 2,023 Depreciation expense 1 323 - 324 Amortization of intangible assets 88 - - 88

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of intellectual property, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable, and collectability is reasonably assured. Deferred revenue represents billings to a customer to whom the services have not yet been provided. The Company’s contract revenue consists primarily of amounts earned under contracts with third-party customers and reimbursed expenses under such contracts. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-25, “ Revenue Arrangements with Multiple Deliverables Revenue Recognition The Company generates (or may generate in the future) contract revenue under the following types of contracts: Fixed-Fee Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured. Time and Materials Under a time and materials contract, the Company charges customers an hourly rate plus reimbursement for other project specific costs. The Company recognizes revenue for time and material contracts based on the number of hours devoted to the project multiplied by the customer’s billing rate plus other project specific costs incurred. Grant Income Grants are recognized as income when all conditions of such grants are fulfilled or there is a reasonable assurance that they will be fulfilled. Grant income is classified as a reduction of research and development expenses. Grant income amounted to approximately $ 44,000 36,000
Inventory Work in Process, Policy [Policy Text Block]	Work in Process Work in process consists primarily of the cost of labor and other overhead incurred on contracts that have not been completed. Work in process totaled $ 0 26,000
Research and Development Expense, Policy [Policy Text Block]	Research and Development The Company accounts for research and development costs in accordance with the FASB ASC 730-10, “ Research and Development
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from three to fifteen years. Assets held under the terms of capital leases are included in fixed assets and are depreciated on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under capital leases are shown within liabilities and are analyzed between amounts falling due within and after one year (see Note 5).
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of ten years and other intellectual property is amortized over a period from 16 23
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency The Company accounts for foreign currency translation pursuant to FASB ASC 830, “ Foreign Currency Matters
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In May 2014, ASU No. 2014-09, “ Revenue from Contracts with Customers Revenue Recognition Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: Step 1: Identify the contract(s) with a customer. Step 2: Identify the performance obligations in the contract. Step 3: Determine the transaction price. Step 4: Allocate the transaction price to the performance obligations in the contract. Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 was scheduled to be effective for annual reporting periods beginning after December 15, 2015, including interim periods within that reporting period. Early application is not permitted. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of Effective Date” Effective January 1, 2016, the Company adopted ASU 2014-12, “ Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period Effective June 30, 2017, the Company adopted ASU 2014-15, “ Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern On January 1, 2017, the Company adopted ASU 2015-17, “ Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes In January 2016, the FASB issued ASU 2016-01, “ Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities In February 2016, the FASB issued ASU 2016-02, “ Leases (Topic 842) Leases (Topic 840) In March 2016, the FASB issued ASU 2016-09, “ Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued ASU 2016-10, “ Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing Revenue from Contracts with Customers. In May 2016, the FASB issued ASU 2016-12, " Revenue from Contracts with Customers (Topic 606): Narrow Scope Improvements and Practical Expedients In August 2016, the FASB issued ASU 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In October 2016, the FASB issued ASU 2016-16, “ Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued ASU 2016-17, “ Consolidation (Topic 810): Interests Held Through Related Parties That Are Under Common Control In January 2017, the FASB issued ASU 2017-01, “ Business Combinations (Topic 805): Clarifying the Definition of a Business In May 2017, the FASB issued ASU 2017-09, “ Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting ” Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements.

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands): September 30, June 30, Facility under capital lease $ 20,000 $ 20,000 Equipment under capital lease 6,000 6,000 Facility improvements 340 332 Medical equipment 914 905 Office equipment and software 256 256 27,510 27,493 Accumulated depreciation – assets under capital lease (2,111) (1,805) Accumulated depreciation – other (131) (99) (2,242) (1,904) Net fixed assets $ 25,268 $ 25,589

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): September 30, June 30, Intellectual property – gross carrying value $ 3,100 $ 3,100 Patents – gross carrying value 2,364 2,346 5,464 5,446 Intellectual property – accumulated amortization (2,127) (2,088) Patents – accumulated amortization (1,580) (1,535) (3,707) (3,623) Net intangible assets $ 1,757 $ 1,823

Capital Lease Obligation (Table

Capital Lease Obligation (Tables)	3 Months Ended
	Sep. 30, 2017
Table Text Block Supplement [Abstract]
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	Future minimum payments under the capitalized lease obligation are due as follows: Fiscal period ending on September 30,: Principal Interest Total 2018 $ 186,593 $ 1,913,407 $ 2,100,000 2019 201,198 1,898,802 2,100,000 2020 216,947 1,883,053 2,100,000 2021 233,928 1,866,072 2,100,000 2022 252,238 1,847,762 2,100,000 Thereafter 24,129,294 33,620,706 57,750,000 Total minimum lease payments 25,220,198 $ 43,029,802 $ 68,250,000 Less: current portion (186,593) Long-term portion of minimum lease obligations $ 25,033,605

Earnings (Loss) Per Common Sh27

Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts): Three Months ended 2017 2016 Basic and diluted numerator: Net loss attributable to iBio, Inc. stockholders $ (3,826) $ (3,061) Preferred stock dividends (66) — Net loss available to iBio, Inc. stockholders $ (3,892) $ (3,061) Basic and diluted denominator: Weighted-average common shares outstanding 91,853 89,109 Per share amount $ (0.04) $ (0.03)

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands): Three Months Ended 2017 2016 Research and development $ 14 $ 6 General and administrative 191 259 Total $ 205 $ 265
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table summarizes all stock option activity during Fiscal 2018: Stock Weighted- Weighted- Aggregate Outstanding as of July 1, 2017 13,548,334 $ 1.21 5.8 $ 138 Granted 50,000 0.40 Outstanding as of September 30, 2017 13,598,334 $ 1.21 5.6 $ 83 Vested and, as of September 30, 2017, expected to vest 13,543,932 $ 1.21 5.6 $ 83 Exercisable as of September 30, 2017 10,911,679 $ 1.30 4.8 $ 83
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions: Risk-free interest rate 2.23 % Dividend yield 0 % Volatility 103.10 % Expected term (in years) 9

Segment Reporting (Tables)

Segment Reporting (Tables)	3 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Three Months Ended September 30, 2017 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 84 $ 38 $ - $ 122 Revenues – intersegment 301 210 (511) - Research and development 618 484 (117) 985 General and administrative 1,099 1,698 (299) 2,498 Operating loss (1,332) (2,029) - (3,361) Interest expense - (480) - (480) Interest and other income 12 2 - 14 Consolidated net loss (1,321) (2,506) - (3,827) Total assets 18,810 27,485 (12,862) 33,433 Fixed assets, net 7 25,261 - 25,268 Intangible assets, net 1,757 - - 1,757 Depreciation expense 1 337 - 338 Amortization of intangible assets 85 - - 85 Three Months Ended September 30, 2016 (in thousands) iBio, Inc. iBio CDMO Eliminations Total Revenues - external customers $ 86 $ 49 $ - $ 135 Revenues – intersegment 152 182 (334) - Research and development 684 321 (185) 820 General and administrative 1,347 1,271 (149) 2,469 Operating loss (1,793) (1,361) - (3,154) Interest expense - (483) - (483) Interest and other income 18 7 - 25 Consolidated net loss (1,775) (1,837) - (3,612) Total assets 11,810 36,330 (49) 48,091 Fixed assets, net 8 25,572 - 25,580 Intangible assets, net 2,023 - - 2,023 Depreciation expense 1 323 - 324 Amortization of intangible assets 88 - - 88

Nature of Business (Details Tex

Nature of Business (Details Textual) $ / shares in Units, $ in Millions	3 Months Ended
	Sep. 30, 2017ft²	Feb. 23, 2017$ / shares	Jan. 13, 2016USD ($)	Dec. 31, 2015
Second Eastern Affilate [Member]
Nature of Business [Line Items]
Area of Land | ft²	139,000
iBio CDMO LLC [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent		99.99%
Equity Method Investment, Ownership Percentage		0.01%
iBio CDMO LLC [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Lease Term	34 years
iBio CMO [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent				100.00%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			70.00%
Equity Method Investment, Ownership Percentage		99.99%
Preferred Stock, Par or Stated Value Per Share | $ / shares		$ 0.001
iBio CMO [Member] | Second Eastern Affilate [Member]
Nature of Business [Line Items]
Noncontrolling Interest, Amount Represented by Preferred Stock | $			$ 15
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners			30.00%

Basis of Presentation (Details

Basis of Presentation (Details Textual) - USD ($)	Apr. 13, 2016	Jul. 24, 2017	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Basis of Presentation [Line Items]
Accumulated deficit			$ (75,949,000)		$ (72,123,000)
Net Cash Used in Operating Activities			(3,017,000)	$ (2,273,000)
Stock Issued During Period, Shares, New Issues	6,500,000
Stock Issued During Period, Value, New Issues	$ 4,043,000		1,000,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total			$ (3,827,000)	$ (3,612,000)
Common Stock, Shares, Issued		1,200,000	92,818,510		89,118,510
Lincoln Park Capital Fund, LLC [Member]
Basis of Presentation [Line Items]
Aggregate Common Stock Purchased		$ 302,017
Stock Issued During Period, Shares, New Issues		2,500,000
Stock Issued During Period, Value, New Issues		$ 1,000,000
Common Stock, Shares, Issued		3

Summary of Significant Accoun32

Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Summary Of Significant Accounting Policies [Line Items]
Revenue from Grants	$ 44	$ 36
Work in process	$ 0		$ 26
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	3 years
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	15 years
Patents [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	10 years
Intellectual Property [Member] | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	16 years
Intellectual Property [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	23 years

Fixed Assets (Details)

Fixed Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016
Property, Plant and Equipment, Gross	$ 27,510	$ 27,493
Accumulated depreciation - assets under capital lease	(2,111)	(1,805)
Accumulated depreciation - other	(131)	(99)
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(2,242)	(1,904)
Net fixed assets	25,268	25,589	$ 25,580
Facility Under Capital Lease [Member]
Property, Plant and Equipment, Gross	20,000	20,000
Equipment Under Capital Lease [Member]
Property, Plant and Equipment, Gross	6,000	6,000
Facility Improvements [Member]
Property, Plant and Equipment, Gross	340	332
Medical equipment [Member]
Property, Plant and Equipment, Gross	914	905
Office Equipment [Member]
Property, Plant and Equipment, Gross	$ 256	$ 256

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Depreciation, Total	$ 338,000	$ 324,000
iBio CDMO LLC [Member] | Second Eastern Affilate [Member]
Lease Term	34 years
Capital Leased Assets [Member]
Depreciation, Total	$ 306,000	$ 311,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	$ 5,464	$ 5,446
Finite-Lived Intangible Assets, Accumulated Amortization	(3,707)	(3,623)
Net intangible assets	1,757	1,823
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	3,100	3,100
Finite-Lived Intangible Assets, Accumulated Amortization	(2,127)	(2,088)
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross carrying value	2,364	2,346
Finite-Lived Intangible Assets, Accumulated Amortization	$ (1,580)	$ (1,535)

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 85	$ 88
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Maximum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	23 years
Minimum [Member] | Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	16 years

Significant Vendors (Details Te

Significant Vendors (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2015	Jun. 30, 2017
Significant Vendor [Line Items]
Accounts Payable, Current	$ 596,000			$ 749,000
Research and Development Expense	985,000	$ 820,000
Revenue, Net, Total	122,000	135,000
Amended Agreement [Member]
Significant Vendor [Line Items]
Research and Development Expense			$ 2,100,000
Revenue, Net, Total	0	62,000
Fraunhofer [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	75,000			75,000
Novici [Member]
Significant Vendor [Line Items]
Accounts Payable, Current	56,000			$ 87,000
Research and Development Expense	$ 176,000	$ 239,000

Capital Lease Obligation (Detai

Capital Lease Obligation (Details) - USD ($)	Sep. 30, 2017	Jun. 30, 2017
2,018	$ 2,100,000
2,019	2,100,000
2,020	2,100,000
2,021	2,100,000
2,022	2,100,000
Thereafter	57,750,000
Total minimum lease payments	68,250,000
Less: current portion	(187,000)	$ (183,000)
Long-term portion of minimum lease obligations	25,034,000	$ 25,082,000
Principal [Member]
2,018	186,593
2,019	201,198
2,020	216,947
2,021	233,928
2,022	252,238
Thereafter	24,129,294
Total minimum lease payments	25,220,198
Less: current portion	(186,593)
Long-term portion of minimum lease obligations	25,033,605
Interest [Member]
2,018	1,913,407
2,019	1,898,802
2,020	1,883,053
2,021	1,866,072
2,022	1,847,762
Thereafter	33,620,706
Total minimum lease payments	$ 43,029,802

Capital Lease Obligation (Det39

Capital Lease Obligation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Capital Leases, Income Statement, Interest Expense	$ 480,000	$ 484,000
Sub Lease Expiration Period	34 years
Operating Leases, Rent Expense	$ 2,100,000
Capital Lease Obligation Description	the base rent, iBio CDMO is required to pay, for each calendar year during the term, a portion of the total gross sales for products manufactured or processed at the facility, equal to 7% of the first $5,000,000 of gross sales, 6% of gross sales between $5,000,001 and $25,000,000, 5% of gross sales between $25,000,001 and $50,000,000, 4% of gross sales between $50,000,001 and $100,000,000, and 3% of gross sales between $100,000,001 and $500,000,000. However, if for any calendar year period from January 1, 2018 through December 31, 2019, iBio CDMOs applicable gross sales are less than $5,000,000, or for any calendar year period from and after January 1, 2020, its applicable gross sales are less than $10,000,000, then iBio CDMO is required to pay the amount that would have been payable if it had achieved such minimum gross sales and shall pay no less than the applicable percentage for the minimum gross sales for each subsequent calendar year. Percentage rent amounted to $17,000 and $16,000 for the three months ended September 30, 2017 and 2016, respectively.

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	Apr. 13, 2016	Apr. 07, 2016	Jan. 13, 2016	May 15, 2015	Jul. 24, 2017	Feb. 23, 2017	Jan. 25, 2016	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2016
Stockholders' Equity [Line Items]
Preferred Stock, Shares Authorized						1,000,000		1,000,000	1,000,000
Common Stock, Shares Authorized								175,000,000	175,000,000	175,000,000
Common Stock, Shares, Issued					1,200,000			92,818,510	89,118,510
Stock Issued During Period, Shares, New Issues	6,500,000
Stock Issued During Period, Value, New Issues	$ 4,043,000							$ 1,000,000
Share Price					$ 0.40
Common Stock, Par or Stated Value Per Share								$ 0.001	$ 0.001
Stockholders [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, Other		6,500,000
Eastern Share Purchase Agreements [Member]
Stockholders' Equity [Line Items]
Proceeds from Warrant Exercises							$ 945,000
Stock Issued During Period, Value, New Issues							$ 2,177,000
Stock Issued During Period, Shares, Other			6,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 0.53
Stock Issued During Period, Shares, Acquisitions			3,500,000
Common Stock, Par or Stated Value Per Share			$ 0.622
Class Of Warrants Or Rights Exercised							1,784,000
Maximum Common Stock Percentage			38.00%
Lincoln Park Purchase Agreement [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased					$ 16,000,000
Stock Issued During Period, Shares, New Issues					2,500,000
Stock Issued During Period, Shares, Other					100,000
Share Price					$ 0.25
Additional Aggregate Common Stock Purchased					$ 15,000,000
Aspire Capital Fund, LLC 2014 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								15,000,000
Aggregate Common Stock Purchased				$ 15,000,000
Aspire Capital Fund, LLC 2015 [Member]
Stockholders' Equity [Line Items]
Commitment Shares Issued During Period				450,000
Preferred Tracking Stock [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period, Shares, New Issues						13,000,000
Stock Issued During Period, Value, New Issues						$ 13,000,000
Preferred Stock, Dividend Rate, Percentage								2.00%
Dividends Payable								$ 156,000
Convertible Preferred Stock, Shares Issued upon Conversion						29,990,000
Preferred Stock, Par or Stated Value Per Share						$ 0.001
Noncontrolling Interest, Ownership Percentage by Parent						99.99%
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners						0.01%
Maximum [Member] | Lincoln Park Purchase Agreement [Member]
Stockholders' Equity [Line Items]
Aggregate Common Stock Purchased					$ 1,000,000

Earnings (Loss) Per Common Sh41

Earnings (Loss) Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Basic and diluted numerator:
Net loss attributable to iBio, Inc. stockholders	$ (3,826)	$ (3,061)
Preferred stock dividends	(66)	0
Net loss available to iBio, Inc. stockholders	$ (3,892)	$ (3,061)
Basic and diluted denominator:
Weighted-average common shares outstanding	91,853	89,109
Per share amount	$ (0.04)	$ (0.03)

Earnings (Loss) Per Common Sh42

Earnings (Loss) Per Common Share (Details Textual) - shares shares in Millions	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Warrant [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants		12.3
Employee Stock Option [Member]
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants	13.6

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 205	$ 265
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	14	6
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 191	$ 259

Share-Based Compensation (Det44

Share-Based Compensation (Details 1) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Options, Outstanding at beginning of the period	13,548,334
Stock Options, Granted	50,000
Stock Options, Outstanding at end of the period	13,598,334	13,548,334
Vested and, as of September 30, 2017, expected to vest	13,543,932
Exercisable as of September 30, 2017	10,911,679
Weighted-average Exercise Price, Outstanding at beginning of the period	$ 1.21
Weighted-average Exercise Price, Granted	0.40
Weighted-average Exercise Price, Outstanding at end of the period	1.21	$ 1.21
Vested and, as of September 30, 2017, expected to vest	1.21
Weighted-average Exercise Price, Exercisable	$ 1.30
Weighted-average Remaining Contractual Term (in years), Outstanding	5 years 7 months 6 days	5 years 9 months 18 days
Weighted-average Remaining Contractual Term (in years), Vested and,Vested and, as of September 30, 2017, expected to vest	5 years 7 months 6 days
Weighted-average Remaining Contractual Term (in years), Exercisable as of June 30, 2017	4 years 9 months 18 days
Aggregate Intrinsic Value ,Outstanding	$ 83	$ 138
Aggregate Intrinsic Value,Vested and, as of September 30, 2017, expected to vest	83
Aggregate Intrinsic Value,Exercisable as of September 30, 2017	$ 83

Share-Based Compensation (Det45

Share-Based Compensation (Details 2)	3 Months Ended
	Sep. 30, 2017
Risk-free interest rate	2.23%
Dividend yield	0.00%
Volatility	103.10%
Expected term (in years)	9 years

Share-Based Compensation (Det46

Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended
	Sep. 30, 2017	Aug. 12, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.34
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)	$ 922,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	1 year 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Other Increases (Decreases) in Period, Description	 Plan was amended to increase the number of shares reserved for awards under the Plan from 10 million to 15 million
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)		10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)	1,450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	50,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.40

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	Apr. 13, 2016	Feb. 23, 2017	Dec. 31, 2015	Nov. 30, 2015	Sep. 30, 2017	Sep. 30, 2016	Mar. 31, 2017	Jun. 30, 2017
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current					$ 56,000			$ 87,000
Research and Development Expense					985,000	$ 820,000
Operating Leases, Rent Expense					$ 2,100,000
Stock Issued During Period, Shares, New Issues	6,500,000
Common Stock, Par or Stated Value Per Share					$ 0.001			$ 0.001
Stock Issued During Period, Value, New Issues	$ 4,043,000				$ 1,000,000
Preferred Tracking Stock [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, New Issues		$ 13,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001
Convertible Preferred Stock, Shares Issued upon Conversion		29,990,000
iBio CDMO LLC [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage		0.01%
Noncontrolling Interest, Ownership Percentage by Parent		99.99%
Eastern Two Share Purchase Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues					10,000,000
Common Stock, Par or Stated Value Per Share					$ 0.622
Class Of Warrants Or Rights Exercised					1,784,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.53
Stock Issued During Period, Value, New Issues					$ 6,220,000
Proceeds from Warrant Exercises					$ 945,520
Eastern Capital Limited and its Affiliates [Member] | Retained Interest [Member]
Related Party Transaction [Line Items]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					70.00%
Eastern Capital Limited and its Affiliates [Member] | iBio CDMO LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Due from (to) Related Party, Total					$ 15,000,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners					30.00%
Second Eastern Affilate [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties, Current					$ 778,000			$ 650,000
Research and Development Expense						167,000
Interest Expense, Debt					480,000	483,000
Other General And Administrative Expense					$ 184,000
Stockholders [Member] | Standstill Agreements [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues					6,500,000
Director [Member] | Standstill Agreements [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage					38.00%
Related Party One [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense							$ 7,500
Related Party [Member]
Related Party Transaction [Line Items]
Operating Leases, Rent Expense			$ 2,500	$ 2,200	$ 22,500	$ 7,500

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jan. 14, 2017	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2015	Dec. 30, 2013	Apr. 30, 2013
Commitments and Contingencies [Line Items]
Research and Development Expense, Total			$ 985,000	$ 820,000
Royalty Guarantees, Commitments, Amount			$ 200,000
Long Term Purchase Commitment Expire Date			Dec. 31, 2015
Commitments [Member]
Commitments and Contingencies [Line Items]
Research Services Agreements Value Fulfilling Commitment		$ 3,000,000
License Costs	$ 30,627
Initial license fee	20,000
Contractual Obligation, Due in Next Twelve Months						$ 78,000
Contractual Obligation, Due in Second Year						$ 161,754
Settlement Agreement [Member]
Commitments and Contingencies [Line Items]
Prepaid Expense							$ 1,000,000
Amended Agreement [Member]
Commitments and Contingencies [Line Items]
Research and Development Expense, Total					$ 2,100,000
Minimum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	25,000
Maximum [Member] | Commitments [Member]
Commitments and Contingencies [Line Items]
License Costs	$ 150,000
Fraunhofer [Member]
Commitments and Contingencies [Line Items]
Royalty Guarantees, Commitments, Amount			$ 4,000,000
Other Commitments, Description			under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2017
Segment Reporting Information [Line Items]
Revenues - external customers	$ 122	$ 135
Revenues - intersegment	0	0
Research and development	985	820
General and administrative	2,498	2,469
Operating loss	(3,361)	(3,154)
Interest expense	(480)	(483)
Interest and other income	14	25
Consolidated net loss	(3,827)	(3,612)
Total assets	33,433	48,091	$ 36,010
Fixed assets, net	25,268	25,580	25,589
Intangible assets, net	1,757	2,023	$ 1,823
Depreciation expense	338	324
Amortization of intangible assets	85	88
Intersegment Eliminations [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	0	0
Revenues - intersegment	(511)	(334)
Research and development	(117)	(185)
General and administrative	(299)	(149)
Operating loss	0	0
Interest expense	0	0
Interest and other income	0	0
Consolidated net loss	0	0
Total assets	(12,862)	(49)
Fixed assets, net	0	0
Intangible assets, net	0	0
Depreciation expense	0	0
Amortization of intangible assets	0	0
iBio CDMO [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	38	49
Revenues - intersegment	210	182
Research and development	484	321
General and administrative	1,698	1,271
Operating loss	(2,029)	(1,361)
Interest expense	(480)	(483)
Interest and other income	2	7
Consolidated net loss	(2,506)	(1,837)
Total assets	27,485	36,330
Fixed assets, net	25,261	25,572
Intangible assets, net	0	0
Depreciation expense	337	323
Amortization of intangible assets	0	0
iBio, Inc [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues - external customers	84	86
Revenues - intersegment	301	152
Research and development	618	684
General and administrative	1,099	1,347
Operating loss	(1,332)	(1,793)
Interest expense	0	0
Interest and other income	12	18
Consolidated net loss	(1,321)	(1,775)
Total assets	18,810	11,810
Fixed assets, net	7	8
Intangible assets, net	1,757	2,023
Depreciation expense	1	1
Amortization of intangible assets	$ 85	$ 88